Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV glycoprotein gp140 + LTK63
- Development stage
- Discontinued
- Lead developer
- Richmond Pharmacology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
HIV glycoprotein gp140 + LTK63 is a combination investigational prophylactic vaccine candidate designed to induce an immune response against human immunodeficiency virus (HIV). The vaccine consists of the recombinant trimeric ectodomain of the HIV-1 envelope glycoprotein (gp140), which mimics the native structure of viral spikes and serves as an immunogen to elicit neutralizing antibodies. Gp140 includes both surface (gp120) and transmembrane (gp41) subunits, engineered for stability and antigenicity. The formulation is adjuvanted with LTK63, a genetically detoxified mutant of Escherichia coli heat-labile enterotoxin B subunit, used as a mucosal adjuvant to enhance immune responses. This combination was developed primarily for prevention of HIV infection through stimulation of humoral immunity but has not demonstrated sufficient efficacy in clinical trials[1][2][4].
- Other names
- HIV gp140 adjuvanted with LTK63HIV-1 envelope glycoprotein gp140 + LTK63
02
Targets
BCR (Immunoglobulin G B Cell Receptor)CD4 (T lymphocyte surface antigen)gp140 (HIV-1 gp140)
Beyond the preview
Go deeper on HIV glycoprotein gp140 + LTK63.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV glycoprotein gp140 + LTK63.